Pfizer Inc (PFE)

PFE on New York Consolidated

30.36USD
20 Nov 2014
Price Change (% chg)

$-0.08 (-0.25%)
Prev Close
$30.44
Open
$30.33
Day's High
$30.49
Day's Low
$30.25
Volume
12,716,527
Avg. Vol
24,108,484
52-wk High
$32.96
52-wk Low
$27.51

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.69
Market Cap (Mil.): $191,792.00
Shares Outstanding (Mil.): 6,300.66
Dividend: 0.26
Yield (%): 3.42

Financials

  PFE Industry Sector
P/E (TTM): 19.25 38.20 39.19
EPS (TTM): 1.58 -- --
ROI: 6.86 17.90 17.21
ROE: 13.42 18.65 18.13
Search Stocks

AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer

LONDON - AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. | Video

18 Nov 2014

UPDATE 3-AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer

* Investor day comes 8 days before Pfizer can resume pursuit

18 Nov 2014

BRIEF-AstraZeneca CEO says "hard to comment" on whether Pfizer will return

Nov 18 - AstraZeneca executives, speaking to reporters: * CEO says hard to comment on read-across from Pfizer/Merck cancer

18 Nov 2014

AstraZeneca trumpets progress in cancer, other drugs

LONDON, Nov 18 - AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs.

18 Nov 2014

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Updates with closing prices)

17 Nov 2014

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Recasts, adds quotes, detail)

17 Nov 2014

European shares pare losses after Japan slips into recession

* Weir hit by renewed slump in crude (Adds detail, quotes, updates prices)

17 Nov 2014

Pfizer dampens Astra bid hopes with German Merck cancer deal

FRANKFURT/LONDON - Pfizer dampened investors' expectations of a renewed bid for AstraZeneca on Monday by signing a major cancer drug deal with Germany's Merck KGaA , reducing the U.S. firm's need for Astra's products.

17 Nov 2014

Pfizer says deal makes it 'competitive' in immuno-oncology

LONDON - Pfizer's deal to buy rights to a promising drug from Germany's Merck KGaA will enable it to compete strongly in the fast-growing field of cancer immunotherapy, its research head said.

17 Nov 2014

UPDATE 2-Pfizer dampens Astra bid hopes with German Merck cancer deal

* Pfizer grabs rights to Merck anti-PD-L1 immunotherapy drug

17 Nov 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $108.17 -0.59
Novartis AG (NOVN.VX) CHF91.50 0.00
Merck & Co., Inc. (MRK.N) $59.21 -0.43
Roche Holding Ltd. (ROG.VX) CHF288.30 0.00
Abbott Laboratories (ABT.N) $43.70 +0.27
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.02 -1.81
AstraZeneca plc (AZN.L) 4,711.00p -55.50
GlaxoSmithKline plc (GSK.L) 1,477.00p +6.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks